Post Profile






Laquinimod Fails to Slow Brain Atrophy and PPMS Progression, Says Developer Active Biotech

Sweden's Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug's potential to treat primary progressive multiple sclerosis. Laquinimod, also known as Nerventra or ABR-215062, was developed by Active Biotech and Israel's Teva Pharmaceutical Industries. The drug targets inflammation and degeneration in neurological tissue.
read more

share

Related Posts


#ACTRIMS2017 – No Evidence of Progression More Likely Among PPMS Patients on Ocrevus

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Genentech’s Ocrevus (ocrelizumab) increased the proportion of patients with no evidence of progression (NEP) in the recently concluded ORATORIO Phase 3 clinical trial in patients with primary progressive multiple sclerosis (PPMS). T...

Remyelination Candidate Opicinumab Failed in Phase 2 Trial in MS, But Biogen Won’t Give Up

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in relapsing and secondary progressive multiple sclerosis (MS)...

Innate to Complete Phase 2b Trial for MIS416 Therapy in Secondary Progressive MS Patients

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Australia’s Innate Immunotherapeutics confirmed that its Phase 2b clinical trial evaluating the drug MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will wrap up by April 30, 2017, as scheduled. MIS416 is a b...

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS) ...

Laquinimod Fails to Meet Primary Clinical Trail Goal of Slowing Progression of RRMS

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Laquinimod failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months, according to its developers, Teva Pharmaceutical Industries and A...

Comments


Copyright © 2016 Regator, LLC